Faut Marloes, Jalving Mathilde, Diercks Gilles F, Hospers Geke A, van Leeuwen Barbara L, Been Lukas B
Department of Surgical Oncology, Department of Surgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700RB Groningen, The Netherlands.
Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700RB Groningen, The Netherlands.
Melanoma Manag. 2018 May 16;5(2):MMT08. doi: 10.2217/mmt-2018-0002. eCollection 2018 Jun.
Neoadjuvant treatment of locally advanced disease with inhibitors is expected to increase the likelihood of a R0 resection. We present six patients with stage III unresectable melanoma, neoadjuvantly treated with inhibitors.
Patients with unresectable, -mutated, stage III melanoma, were treated with inhibitors between 2012 and 2015. Unresectability was determined based on clinical and/or radiological findings. At maximal response, resection was performed. The specimen was reviewed to determine the degree of response.
In five of six patients a radical resection was achieved. Postoperative complications were unremarkable. In five of six resected specimens, vital tumor tissue was found.
Neoadjuvant inhibitor treatment of locally advanced melanoma is feasible and has the potential to facilitate an R0 resection.
使用抑制剂对局部晚期疾病进行新辅助治疗有望提高R0切除的可能性。我们报告了6例接受抑制剂新辅助治疗的III期不可切除黑色素瘤患者。
2012年至2015年间，对不可切除、携带特定基因突变的III期黑色素瘤患者使用抑制剂进行治疗。根据临床和/或影像学检查结果确定不可切除性。在达到最大反应时进行切除。对标本进行评估以确定反应程度。
6例患者中有5例实现了根治性切除。术后并发症不明显。在6个切除标本中的5个中发现了存活的肿瘤组织。
对局部晚期黑色素瘤进行新辅助抑制剂治疗是可行的，并且有可能促进R0切除。
